The marketplace can't give us the drug safety data we need

MedGenMed Medscape General Medicine

Volumn 9, Issue 1, 2007, Pages

  Avorn, Jerry ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROFECOXIB;

CLINICAL STUDY; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; MEDICAID; POSTMARKETING SURVEILLANCE; PROSPECTIVE PAYMENT; STROKE; DRUG TOXICITY; ECONOMICS; MARKETING; METHODOLOGY; UNITED STATES;

DRUG APPROVAL; DRUG INDUSTRY; DRUG TOXICITY; HUMANS; MARKETING; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33846941243     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (3)

1. Baciu A, Stratton K, Burke SP, eds. The Future of Drug Safety: Protecting the Health of the Public. Washington, DC: Institute of Medicine, National Academics Press; 2006.
2. Government Accountability Office. Drug Safety: Improvement Needed in FDA's Post-Market Decision-Making and Oversight Process. GAO Report 06-402. Washington, DC: Government Accountability Office; 2006.
3. Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Knopf; 2005.